Johnson & Johnson's Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of its antibiotic Levaquin.
A new study says doctors in the Southern part of the U.S. are too often prescribing drugs for elderly patients that can have severe side effects and for which there are better alternatives.
Johnson & Johnson has scored a partial court victory in its long-running battle over the antibiotic Levaquin. The drugmaker has faced thousands of lawsuits claiming Levaquin caused tendon injuries--and that J&J didn't do enough to warn patients and doctors of the risk.
For the second quarter in a row, Johnson & Johnson posted a downward tick in revenues, hobbled by currency losses. Asset writedowns, legal-settlement set-asides, and acquisition costs dug into earnings.
Johnson & Johnson's first-quarter sales may have taken a hit, but its prescription drugs business actually grew.
FDA advisors have backed approval for Levaquin for a new use that the federal government had pushed for.
Johnson & Johnson ($JNJ) has prevailed in its latest court fight over the antibiotic Levaquin. A New Jersey jury found J&J's Ortho-McNeil-Janssen unit wasn't liable for tendon injuries
A jury in Minneapolis has decided that Johnson & Johnson isn't responsible for an 84-year-old's ruptured Achilles tendon and properly warned of the risks posed by its antibiotic Levaquin. The
Another product liability suit has hit the courts. This time it's Johnson & Johnson's Levaquin at issue, with an 84-year-old plaintiff alleging that he ruptured his Achilles tendon after taking
A Minnesota jury has determined that Johnson & Johnson did not properly warn patients of possible tendon damage from taking the powerful antibiotic Levaquin. John Schedin, the defendant in the